BACKGROUND: Breast cancer tends to respond differently to treatments, which are usually determined by clinicopathological characteristics. Several studies evaluated the role of the peripheral blood test as diagnostic and prognostic markers in several types of solid cancer and neutrophil-to-lymphocyte ratio (NLR) and platelet-tolymphocyte ratio (PLR) are two of them which already tested. However, the evidence in breast cancer is still lacking. AIM: Therefore, the study aimed to investigate the value of NLR and PLR as biomarkers concerning breast cancer stage. METHODS: A retrospective study was conducted using breast cancer patients’ medical records from 2014 to 2019 at Sanglah General Hospital. The histopathological records and complete blood counts of the patients were collected and analyzed risk analysis model, receiver operator characteristics analysis, and correlation of NLR and PLR with cancer staging analysis used correlation test. RESULT: One hundred five patients data were used in this study, with 35 subjects had early-stage breast cancer while 70 subjects had an advanced stage. Breast cancer staging with NLR and PLR showed significant associations (p < 0.001). Both NLR and PLR had area under the curve >0.7 (p < 0.001). The cutoff, sensitivity, and specificity values of NLR and PLR were 2.504 (71%; 70%) and 157.1 (73%; 70%). Advanced stage of breast cancer was mostly found in high NLR and PLR value with (OR: 4.231; CI = 1.791-9.995, p < 0.001) and (OR: 3.949; 95% CI = 1.679–9.287; p < 0.001). CONCLUSION: From this preliminary study, pretreatment NLR and PLR values might determine the breast cancer stage. Further research is needed to evaluate the association between grade and patient survival.

BACKGROUND: Soil-transmitted helminths (STHs) infection is an infectious disease that has a high prevalence with unclear clinical symptoms and predominantly affects children in the age range of 5–14 years. AIM: This study aims to determine the prevalence and risk factors for STH infections in elementary school students in an STH endemic area. METHODS: This study was an observational analytic study with a cross-sectional design with a total sampling method. Risk factors were obtained by a questionnaire, and the diagnosis of STH infection was established through a fecal examination with the modified Kato-Katz method. The data are then processed and analyzed using the SPSS application. Chi-square test and risk assessment are used to determine risk factors for STH infection. RESULTS: A total of 138 children participated in this study. The prevalence of STH infections obtained was 56.5% with Trichuris trichiura (53.8%), Ascaris lumbricoides (18%), and both (28.2%) as etiology. The degree of STH infection varies from mild-to-severe. All risk factors related to hygiene and sanitation have a statistically significant relationship with the prevalence of STH infections. Eating while playing on the ground was the most influential risk factor for the high prevalence of STH infections (p <0.001, PR = 2.611, CI 95% = 1.961–3.477). CONCLUSION: The prevalence of STH infections in elementary schoolchildren in Tenganan village was 56.5%. Low personal hygiene and sanitation are risk factors for STH infection that can be overcome; therefore, it is necessary to introduce early prevention efforts in elementary schoolchildren as one risk group for STH infection.

Ovarian cancer is one of the major health problems in gynecology worldwide. Globocan 2012 data shows that ovarian cancer occurs in 239.000 cases, and is placed fourth as the most malignancy occurred in Indonesia. So far, cisplatin is the most effective therapeutic agent, but the high dosage of administration often caused side effects. A new alternative therapy to overcome the problems by using withaferin-A and nanoparticle PEGylated liposome. WFA has the potential effect to reduce cisplatin resistance but has low bioavailability thus, it needs to be encapsulated. This review's goal is to depict the potency of withaferin-A, cisplatin, and PEGylated liposome combination as a therapeutic agent to treat ovarian cancer. The combination of Cisplatin-Withaferin PEGylated Liposome is constructed by the modified thin lipid film hydration method then administered orally. This combination suppresses 70-80% of the ovarian cancer cell growth in vivo and inhibits NGFR from binding to TRKA, prevents cell migration as much as 50%. Nano-Cisferin-Liposome, inhibits migration of ovarian cancer cell significantly through β-catenin signaling through ALDH1 that disturb the spheroid formation, and increase apoptosis event as much 70-80% by increasing ROS production up to 2,5 times. Thus, Nano-Cisferin-Liposome (NCL) has potential as a therapeutic agent for treating ovarian cancer. AbstrakKanker ovarium merupakan masalah kesehatan ginekologi wanita di dunia. Data Global Burden Cancer (Globocan) tahun 2012 menunjukkan kanker ovarium terjadi sebanyak 239.000 kasus, dan menempati urutan ke-empat di Indonesia. Hingga kini, Cisplatin merupakan agen terapi andalan untuk kanker ovarium namun sering menimbulkan efek samping dalam dosis tinggi. Terapi alternatif dapat menjadi solusi untuk mengatasi masalah tersebut dengan memanfaatkan withaferin A (WFA) serta nanopartikel PEGylated liposome. WFA sangat potensial untuk mengurangi resistensi Cisplatin, tetapi memiliki bioavailabilitas rendah sehingga perlu dienkapsulasi. Tujuan tinjauan ini yaitu untuk menggambarkan potensi kombinasi withaferin A, cisplatin, dan PEGylated liposome sebagai pengobatan untuk kanker ovarium. Tinjauan pustaka ini dilakukan dengan menggunakan kata: "kanker ovarium, Withaferin A, Cisplatin dan PEGylated liposome" sebagai kata kunci pada mesin pencarian. Kombinasi Cisplastin-Withaferin dan nanopartikel PEGylated Liposom dilakukan dengan metode thin lipid film hydration yang termodifikasi kemudian diberikan melalui jalur oral. Kombinasi Cisplastin-Withaferin ini dapat menekan pertumbuhan kanker ovarium sebesar 70-80% secara in vivo, menghambat NGFR berikatan dengan TRKA sehingga mencegah terjadinya migrasi sel sebesar 50%, menghambat migrasi sel kanker secara signifikan melalui jalur persinyalan β-catenin oleh ALDH1, meningkatkan apoptosis sebesar 70-80% melalui peningkatan produksi ROS hingga 2,5 kali lipat, serta mampu mengeliminasi CSC. Karena itu, kombinasi ini merupakan salah satu terapi potensial dalam penatalaksanaan kanker ovarium. Kata kunci: Cisplatin; kanker ova...

Background: Melanoma is the most serious lethal skin cancer, affects the melanin producer cells (melanocytes). Surgery is the most common treatment, whereas for the advance stage the development of a treatment is recommended. BRAF (Dabrafenib and Vemurafenib) inhibitor or MEK inhibitor (Trametinib) is used as the most frequently targeted therapy of melanoma due to more than 80% patient with positive BRAF mutation. In this review, those treatments will be investigated systematically to identify their clinical outcome.Method: This systematic literature review (SLR) was performed from Cochrane, Science Direct, Google Scholar, and Pubmed. Cochrane Risk-of-Bias Tool RoB2 is used to assess RCT studies and New-castle Ottawa Scale Assessment to assess cohort studies by 3 different assessors. Data analysis was carried out by using Review Manager (RevMan 5.4). Heterogenicity test was assessed by I2  and Chi2 statisticResult: There are 20 studies used in this article (13 RCT and 7 cohorts). The overall survival (OS) and progression-free survival (PFS) of study that using targeted therapy (vemurafenib, trametinib, or dabrafenib) compare other therapies (chemotherapy, immunotherapy,etc) showed risk ratio (RR) was 1.12 (95%CI 1.07,1.17;  I2=100%; p<0,00001). The OS and PFS with monotherapy compare of vemurafenib, trametinib, or dabrafenib with combination therapy showed RR was 1.09 (95%CI.06,1.13;I2=99%; p<0,00001). Conclusion: BRAF and MEK targeted therapy has a good prognosis for a patient with a positive BRAF gene mutation and could be combined with other therapy for a better clinical outcome rather than monotherapy.Keyword: melanoma, dabrafenib, vemurafenib, and trametinib

BACKGROUNDS: Breast cancer or breast carcinoma is the most common type of malignancy in women globally. According to the previous studies that indicate the usage of antihypertensive drugs may become a risk factor of cancer (beta-blockers [BBs], calcium channel blockers [CCBs], and diuretics). Both angiotensin-converting enzymes inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), on the other hand, have been associated to an increased or decreased risk of breast cancer. AIM: To compare each type of antihypertensive medicines as a risk factor for breast cancer, we did a systematic review and meta-analysis of current evidence. METHODS: We utilized the terms “antihypertensive”, “anti-hypertensive”, “anti-hypertensive medications”, “breast cancer”, “risk”, “case control”, and “cohort” in PubMed, ScienceDirect, and Google Scholar databases. RESULTS: Our data calculation found that the risk of antihypertensive drugs was significantly different in overall analysis (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.42–0.83, p = 0.003). Five studies with 39.503 breast cancer patients and 372.037 controls were included in the ARBs user sub-group. Our results found significant different of antihypertensive drugs among breast cancer patient (OR = 1.47, 95% CI = 1.02–2.11 p = 0.04). Our data calculation also confirmed no significant different in antihypertensive drugs among breast cancer patient (OR = 1.07, 95% CI = 0.99–1.16, p = 0.09) in diuretics user, (OR = 1.08, 95% CI = 0.99–1.18, p = 0.08) in CCBs user, (OR = 1.11, 95% CI = 0.98–1.26, p = 0.09) in BBs user, and (OR = 1.27, 95% CI = 0.64–2.50, p = 0.50) in ACEIs user. CONCLUSIONS: Although, the finding reveal that antihypertensive drugs (diuretics, CCBs, BBs, and ACEIs) in overall are significant for the risk of breast cancer and also found that ARBs have a low potential in the risk of breast cancer.